Abstract:Objectives: The coronavirus disease 2019 (COVID-19) is still a global health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The functional entry receptor utilized by SARS-CoV-2 is Angiotensin-Converting Enzyme 2 (ACE2). ACE2 is a key modulator of the Renin-Angiotensin System (RAS), which plays an essential role in human physiology. During the early phase of COVID-19, controversies remained regarding whether COVID-19 patients with underlying conditions have aberrant expression of ACE2 and if ACE2 levels correlate with the severity of COVID-19. Currently, limited data provide a relationship between ACE2 expression and COVID-19 pathogenesis and mortality. We hypothesize that a positron emission tomography (PET) radiotracer with high binding affinity and selectivity can be used to determine whole-body ACE2 levels in vivo. Therefore, the study aims to rationally design and synthesize new ACE2 inhibitors targeting ACE2 in animal models. Methods: A series of ACE2 compounds were designed based on a known ACE2 inhibitor MLN-4760 (IC 50 = 0.44 nM against soluble human ACE2). The probes and reference compound MLN-4760 were modeled into ACE2 using Schrodinger’s Glide. Following docking, full atom refinement was performed using Prime MM-GBSA for the ligands. Next, the new compounds were synthesized in eight steps through functional group protection, alkylation, deprotection, reductive amination reaction, hydrolysis, and diastereomeric separation to obtain four pairs of diastereoisomers. Results: Eight new ACE2 compounds and four pairs of diastereoisomers with one (or two) fluorine-19 atoms were designed. The lead compound, MLN-4760, makes several interactions with ACE2. Molecular modeling suggested that adding fluorine in the para position is tolerated within the binding site, allowing the probe to bind with essentially the same pose as MLN-4760, regardless of stereochemistry. However, replacing a chlorine with a fluorine had a disruptive effect. All the probes were scored and ranked. ( R, S)-1c is able to bind a pose that is highly overlapping MLN-4760, resulting in a similar docking score to MLN-4760. Furthermore, the eight compounds were synthesized by traditional organic chemistry procedures. The target compounds were characterized by 1 H NMR, 13 C NMR, 19 F NMR, LC-mass, and HPLC with over 95% chemical purity and 95% diastereoselective values. Conclusions: A series of fluorine-19 containing inhibitors targeting ACE2 were designed and synthesized with high chemical purity and diastereoisomeric purity. Molecular modeling suggests that the fluorine-19 substitution will be well tolerated, and these compounds are expected to have similar potency to the lead compound, MLN-470. The binding assay of the newly synthesized compounds for ACE2 and selectivity over ACE1 is ongoing. The work was supported by the NIH R21 grant EB032025 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB); the Nemours Diagnostic & Research PET/MRI Center; the Departments of Radiology and Biomedical Research at Nemours Children's Hospital, Delaware. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

An ACE2 PET Imaging Agent Derived from 18f/cl Exchange of MLN-4760 under Phase Transfer Catalysis

Preclinical Evaluation and Pilot Clinical Study of 18F-Labeled Inhibitor Peptide for Noninvasive Positron Emission Tomography Mapping of Angiotensin Converting Enzyme 2

Preclinical Evaluation and Pilot Clinical Study of Al18F-DX600-BCH for non-invasive PET Mapping of Angiotensin Converting Enzyme 2 in Mammal

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Organomediated Cleavage of Benzoyl Group Enables an Efficient Synthesis of 1-(6-nitropyridin-2-yl)thiourea and Its Application for Developing 18F-Labeled PET Tracers.

Microfluidics for synthesis of peptide-based PET tracers.

Radiosynthesis and Evaluation of 4-(6-[18f]fluoro-4-(5-isopropoxy-1h-indazol-3-yl)pyridin-2-yl)morpholine As a Novel Radiotracer Candidate Targeting Leucine-Rich Repeat Kinase 2.

Development of a Radiotracer for PET Imaging of the SNAP Tag.

Development of a CCR2 targeted 18F-labeled radiotracer for atherosclerosis imaging with PET

Single Step 18F-Labeling of Dimeric Cyclorgd for Functional PET Imaging of Tumors in Mice.

Evaluation of 68Ga- and 177Lu-Labeled HZ20 Angiotensin-Converting Enzyme 2-Targeting Peptides for Tumor-Specific Imaging.

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.

Synthesis and preclinical evaluation of a novel fluorine-18 labeled small-molecule PET radiotracer for imaging of CXCR3 receptor in mouse models of atherosclerosis

Synthesis, radiolabeling, and evaluation of a potent β-site APP cleaving enzyme (BACE1) inhibitor for PET imaging of BACE1 in vivo

Synthesis and Characterization of [18F]JNJ-46356479 as the First 18F-Labeled PET Imaging Ligand for Metabotropic Glutamate Receptor 2

Rational design and synthesis of angiotensin-converting enzyme 2 inhibitors targeting severe acute respiratory syndrome coronavirus 2

18 F-Labeled Derivatives of Irbesartan for Angiotensin II Receptor PET Imaging

Dual-Targeting PET Tracers Enable Enzyme-Mediated Self-Assembly for the PET Imaging of Legumain Activity

Synthesis and Evaluation of an 18F-Labeled Bradykinin B1 Receptor-Targeting Small Molecule for PET Imaging

Rationalizing the Binding Modes of PET Radiotracers Targeting the Norepinephrine Transporter